12:00 AM
Mar 25, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Victoza liraglutide: Phase IIIa data

Top-line data from the double-blind, international Phase IIIa SCALE Diabetes trial in 846 overweight or obese Type II diabetics showed that once-daily 1.8 and 3 mg doses of subcutaneous liraglutide both met the 3 co-primary endpoints of reducing mean body weight from baseline to week 56 (5% and 6%, respectively, vs. 2%) and of increasing the proportion of patients who achieved weight loss of >=5% (35% and 50%, respectively, vs. 13%) and >10% (13% and 22%, respectively, vs. 4%) of baseline body weight at week 56 vs. placebo. On secondary endpoints, 67% of patients receiving low-dose liraglutide and 69% of patients receiving high-dose liraglutide achieved an HbA1c...

Read the full 514 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >